Development of LC-MS/MS Quantification of the Novel Antimicrobial Peptide, SR-0379, and its Pharmacokinetics in Rats
During the preclinical study of the original functional peptide, SR-0379, a sensitive liquid chromatographytandem mass spectrometry method was newly developed to study the pharmacokinetics of SR-0379 in rat plasma and subcutaneous tissue samples. Although SR-0379 was unstable in the rat plasma and subcutaneous tissue samples, pretreatment with EDTA and phosphoric acid (4 %) inhibited its degradation. The lower limits of quantification (LLOQ) for SR- 0379 were fully validated as 5 ng/ml in plasma and 5 ng/g in tissue with acceptable linearity, intra- and inter-assay precisions, and accuracy. Measurement of SR-0379 concentration in plasma after intravenous injection via LC-MS/MS yields plasma concentration-time curves (AUC0-∞) with areas of 667 ng.min/ml and an elimination half-life (t1/2) of 4.8 min. The concentration of SR-0379 in the subcutaneous tissue samples was 13.1 µg/g tissue at 30 minutes after a single dermal application (1 mg/ml, 50 µl) to a full-thickness excisional wound. Here, a highly sensitive and specific LC-MS/MS assay with a lower limit of quantification of 5 ng/ml was developed and validated to quantify SR-0379 in rat plasma. This method is useful for pharmacokinetic studies of the peptide drugs in rats..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Immunology, endocrine & metabolic agents in medicinal chemistry - 14(2014), 1, Seite 26-31 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tomioka, Hideki [VerfasserIn] |
---|
Links: |
---|
BKL: |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
OLC1986720721 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC1986720721 | ||
003 | DE-627 | ||
005 | 20230518124702.0 | ||
007 | cr uuu---uuuuu | ||
008 | 170131s2014 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a fidpha_zeitschriften_20170130.pp |
035 | |a (DE-627)OLC1986720721 | ||
035 | |a (DE-599)GBVOLC1986720721 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |
084 | |a PHARM |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Tomioka, Hideki |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development of LC-MS/MS Quantification of the Novel Antimicrobial Peptide, SR-0379, and its Pharmacokinetics in Rats |
264 | 1 | |c 2014 | |
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a During the preclinical study of the original functional peptide, SR-0379, a sensitive liquid chromatographytandem mass spectrometry method was newly developed to study the pharmacokinetics of SR-0379 in rat plasma and subcutaneous tissue samples. Although SR-0379 was unstable in the rat plasma and subcutaneous tissue samples, pretreatment with EDTA and phosphoric acid (4 %) inhibited its degradation. The lower limits of quantification (LLOQ) for SR- 0379 were fully validated as 5 ng/ml in plasma and 5 ng/g in tissue with acceptable linearity, intra- and inter-assay precisions, and accuracy. Measurement of SR-0379 concentration in plasma after intravenous injection via LC-MS/MS yields plasma concentration-time curves (AUC0-∞) with areas of 667 ng.min/ml and an elimination half-life (t1/2) of 4.8 min. The concentration of SR-0379 in the subcutaneous tissue samples was 13.1 µg/g tissue at 30 minutes after a single dermal application (1 mg/ml, 50 µl) to a full-thickness excisional wound. Here, a highly sensitive and specific LC-MS/MS assay with a lower limit of quantification of 5 ng/ml was developed and validated to quantify SR-0379 in rat plasma. This method is useful for pharmacokinetic studies of the peptide drugs in rats. | ||
700 | 1 | |a Nakagami, Hironori |e verfasserin |4 aut | |
700 | 1 | |a Sano, Tomokazu |e verfasserin |4 aut | |
700 | 1 | |a Takafuji, Kazuaki |e verfasserin |4 aut | |
700 | 1 | |a Takashima, Seiji |e verfasserin |4 aut | |
700 | 1 | |a Kaneda, Yasufumi |e verfasserin |4 aut | |
700 | 1 | |a Morishita, Ryuichi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Immunology, endocrine & metabolic agents in medicinal chemistry |d San Francisco, Calif. : Bentham Science Publ., 2006 |g 14(2014), 1, Seite 26-31 |w (DE-627)507526643 |w (DE-600)2221719-8 |w (DE-576)435514261 |x 1871-5222 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2014 |g number:1 |g pages:26-31 |
856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5222&volume=14&issue=1&spage=26 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_20 | ||
936 | b | k | |a 44.40 |q AVZ |
951 | |a AR | ||
952 | |d 14 |j 2014 |e 1 |h 26-31 |